Wegovy Online: How to Get a Legitimate Prescription, Real Costs, and Who Qualifies

Can You Get Wegovy Online?

Yes, but "getting Wegovy online" means completing a real medical visit, not placing an order. Wegovy is a prescription-only injectable, so any site letting you add it to a cart without a clinician reviewing your health history is operating outside the law. Legitimate telehealth platforms collect your weight, BMI, medications, and conditions, then a licensed prescriber decides whether semaglutide is appropriate before anything ships.

How Legitimate Online Wegovy Prescriptions Work

A real online pathway looks almost identical to an in-person visit, just conducted by video or through a secure questionnaire reviewed by a clinician. You submit your medical history, current medications, and prior weight-loss attempts. A physician, nurse practitioner, or physician assistant reviews the intake, may ask follow-up questions, and either approves, modifies, or declines the request based on FDA labeling and your individual risk factors 2.

Red Flags That Signal an Illegitimate Seller

Watch for sites selling Wegovy without any health questionnaire, without a licensed prescriber listed, or shipping from unverified pharmacies. The FDA has repeatedly flagged unauthorized sellers offering semaglutide products of uncertain origin, purity, or dosing accuracy, particularly outside the regulated compounding pathway 3. If a site skips medical review entirely, it is not offering Wegovy legally, whatever the marketing claims.

How Much Does Wegovy Cost?

Wegovy carries a list price near $1,349 per month, though almost nobody pays that figure in full. Actual out-of-pocket cost depends heavily on insurance coverage, manufacturer savings programs, and whether your plan covers obesity medications at all. Many commercially insured patients pay far less; uninsured cash-pay patients often face the full list price unless they use a savings card or switch to a compounded option.

List Price vs. Cash Pay

Cash-pay pricing for branded Wegovy averages around $1,349 monthly according to current manufacturer list pricing, though pharmacy-to-pharmacy variation exists. This figure does not include the injector pen device fee some pharmacies bill separately, and it assumes no insurance contribution whatsoever.

Insurance and Savings Programs

Coverage for obesity medications remains inconsistent across payers. Some employer plans exclude weight-loss drugs entirely, some Medicaid programs cover them selectively, and Medicare Part D historically excluded weight-loss indications, though coverage rules continue to shift. Ask your telehealth provider to check prior authorization requirements before you commit to a specific pharmacy.

Compounded Semaglutide as a Lower-Cost Bridge

Compounded semaglutide, prepared by a licensed compounding pharmacy rather than manufactured as branded Wegovy, averages closer to $199 per month through telehealth clinics. It is not FDA-approved as a standalone product the way Wegovy is, and quality depends entirely on the compounding pharmacy's standards 3. For patients priced out of branded Wegovy, HealthRX's compounded semaglutide program offers a physician-supervised, lower-cost route worth discussing with your prescriber.

Who Is a Candidate for Wegovy?

Wegovy is FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher combined with a weight-related condition like hypertension, type 2 diabetes, or high cholesterol 2. It is also approved for adolescents 12 and older meeting specific weight criteria. Candidacy is not just a BMI cutoff; your prescriber weighs personal and family medical history too.

FDA-Approved Candidacy Criteria

The label criteria are specific. Adults need BMI >=30 alone, or BMI >=27 plus at least one weight-related comorbidity. There is no upper age limit stated in the label, but older adults and those with reduced kidney function require closer monitoring. The Endocrine Society's clinical practice guideline on obesity pharmacotherapy echoes this threshold-based approach and stresses individualized risk assessment over BMI alone 6.

Who Should Not Use Wegovy

Semaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, per FDA labeling 2. Pregnancy, active gallbladder disease, and a history of pancreatitis also warrant caution and a conversation with your prescriber before starting.

A quick candidacy checklist, synthesized from FDA labeling and STEP-1 subgroup data:

• BMI >=30, or >=27 with hypertension, prediabetes, type 2 diabetes, or dyslipidemia
• No personal or family history of medullary thyroid carcinoma or MEN2
• No active pancreatitis, no current pregnancy or plans to conceive soon
• Willing to tolerate a slow four-month dose titration and possible GI side effects
• Realistic expectations: STEP-1 patients lost 14.9% of body weight on average over 68 weeks, not overnight 1
• No response, or minimal response, to prior lifestyle-only weight-loss attempts

None of this replaces an individual medical evaluation. It is meant to help you decide whether a telehealth visit is worth scheduling.

What Does the Clinical Evidence Show?

The strongest evidence for semaglutide 2.4 mg comes from the STEP program, a series of randomized trials published in major peer-reviewed journals. STEP-1 remains the reference trial: 1,961 adults without diabetes lost an average of 14.9% of body weight at 68 weeks on semaglutide versus 2.4% on placebo 1. Nausea, diarrhea, and vomiting were the most common side effects, mostly during dose escalation.

STEP-1: The Landmark Trial

STEP-1 randomized participants 2:1 to semaglutide or placebo, both alongside lifestyle intervention including a reduced-calorie diet and increased physical activity. Roughly 86% of semaglutide-treated participants lost at least 5% of their starting weight, compared with 31.5% on placebo 1. Discontinuation due to gastrointestinal side effects occurred in about 4.5% of the semaglutide group, a modest but real number worth discussing with your prescriber ahead of time.

Beyond Semaglutide: Next-Generation Agents

Research has not stopped at semaglutide. Retatrutide, a triple-hormone-receptor agonist targeting GLP-1, GIP, and glucagon receptors, produced mean weight reductions up to 24.2% at the highest dose in a phase 2 trial over 48 weeks 4. It is not FDA-approved and remains investigational, so it is not available through any legitimate prescription pathway today, online or otherwise. Treat any site claiming to sell it as a red flag.

How to Get Wegovy: The Online Visit Process

Getting Wegovy through telehealth follows a fairly standard four-step sequence at reputable clinics. You complete an intake questionnaire, a licensed clinician reviews your history, a decision gets made, and if approved, the prescription routes to a pharmacy for fulfillment. The entire process typically takes anywhere from same-day to about a week depending on documentation needs.

Step 1: Intake and Health History

Expect questions on current weight, height, blood pressure, prior weight-loss medications, thyroid history, pregnancy status, and any GI conditions. Some platforms request recent labs or ask you to upload existing records rather than order new bloodwork.

Step 2: Clinician Review

A physician, nurse practitioner, or physician assistant reviews your submission against FDA labeling criteria and any contraindications. This step is where a legitimate service differs sharply from a site simply processing payment. Expect possible follow-up questions by message or short video call.

Step 3: Prescription and Pharmacy Routing

If approved, your prescription routes electronically to a licensed pharmacy, either your local pharmacy or a mail-order option the platform partners with. Dosing typically starts low (0.25 mg weekly) and escalates over about 16 to 20 weeks toward the 2.4 mg maintenance dose, per the FDA-approved titration schedule 2.

Wegovy vs. Compounded Semaglutide: What's the Real Difference?

Wegovy is an FDA-approved, brand-name product manufactured under strict quality controls and tested in the trials described above. Compounded semaglutide is prepared by a licensed compounding pharmacy, usually during periods of branded drug shortage, and is not independently FDA-approved as a finished product 3. Both require a prescription; only one carries FDA approval for the specific dose and formulation sold.

Cost is the main reason patients consider compounding. At roughly $199 per month versus $1,349 for branded Wegovy, the price gap is substantial for someone paying entirely out of pocket. The tradeoff is regulatory oversight: compounded products are not FDA-reviewed for the specific weight-loss claim, and quality varies by pharmacy. Discuss this tradeoff openly with your prescriber, and ask specifically which compounding pharmacy fills the prescription and what quality testing it performs.

What Are the Side Effects and Safety Considerations?

Gastrointestinal side effects dominate the safety profile of semaglutide 2.4 mg. Nausea, diarrhea, vomiting, and constipation affected a meaningful share of STEP-1 participants, generally clustering around dose increases rather than staying constant throughout treatment 1. Most cases were described as mild to moderate and improved with slower titration or dietary adjustment.

Rare but serious risks include pancreatitis, gallbladder disease, and, based on animal studies, a theoretical thyroid tumor risk that led to the medullary thyroid carcinoma contraindication on the label 2. Report severe abdominal pain, vision changes, or signs of an allergic reaction to your prescriber immediately rather than waiting for a scheduled follow-up. Given that over 40% of U.S. Adults meet criteria for obesity according to CDC surveillance data, demand for evaluation continues to outpace supply at many clinics, so book your visit before assuming same-day availability 5.